This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Biomarkers Circulation Outcomes 
European Journal of Heart Failure
JANUARY 17, 2025
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end-organ dysfunction.
Heart BMJ
JANUARY 29, 2025
Background We evaluated the potential of circulating bone morphogenetic protein 10 (BMP10) as a biomarker for atrial stress and remodelling in patients with heart failure (HF), in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP). We also assessed the predictive value of BMP10 for adverse clinical outcomes.
Circulation: Heart Failure
MARCH 14, 2025
Circulation: Heart Failure, Ahead of Print. The genotype-phenotype interdependence causes unpredictable phenotypic penetrance that results in a variety of signs and symptoms and patient outcomes. Cardiovascular biomarkers and multimodality imaging may identify initial amyloidogenic organ involvement.
HCPLive
AUGUST 16, 2024
Strnad explains the need for noninvasive biomarkers in AATD liver disease and early research about circulating Z-polymer’s potential association with clinically relevant adverse outcomes.
52 
Frontiers in Cardiovascular Medicine
FEBRUARY 11, 2024
In this review, we summarize the diagnostic and prognostic tools for ICI-myocarditis, including electrocardiography, echocardiography, cardiac magnetic resonance imaging, with emphasis on circulating biomarkers.
64 
HCPLive
JULY 30, 2024
Greater circulating Z-polymer levels were associated with an increased risk of adverse clinical outcomes in adults with AATD and the PiZZ genotype.
52 Stroke Journal
JANUARY 30, 2025
Background:The effect of renal dysfunction on early infarct growth rate (IGR) in anterior circulation large vessel occlusion (ACLVO) stroke is not well studied. Stroke, Volume 56, Issue Suppl_1 , Page AWP88-AWP88, February 1, 2025. mg/dL, p < 0.05) and lower median eGFR (66.2 mL/min/1.73m2, p < 0.05).
40 
Circulation
MARCH 9, 2025
Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Urinary albumin-to-creatinine ratio is an attractive, unifying biomarker of cardiovascular, kidney, and metabolic conditions that may be useful for identifying and monitoring disease trajectory.
Circulation: Cardiovascular Quality & Outcomes
JANUARY 19, 2024
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Background:Serum troponins and CK-MB (creatine kinase-MB) are readily detectable and reliable cardiac-specific biomarkers of subclinical myocardial injury. This study explores the roles of cTnI (cardiac troponin I) and CK-MB in hypertrophic cardiomyopathy (HCM).Methods:This
40 
Stroke Journal
JANUARY 30, 2025
Background:Endovascular thrombectomy (EVT) dramatically improves clinical outcomes, but the final infarct volume (FIV) on MRI only accounts for a minority of the treatment effect. Consecutive anterior circulation EVT patients were included from 2018-2019 who achieved successful reperfusion (mTICI 2b). per 1mL; 95%CI: 0.98-1.00;
40 
Stroke Journal
JANUARY 30, 2025
Introduction:Endovascular thrombectomy (EVT) dramatically improves clinical outcomes, but the reduction in final infarct volume only accounts for a minority of the treatment effect. Good functional outcome was defined as a 90-day modified Rankin Scale score 2. MRI was performed 1248 hours post-EVT. vs 30.3%, p<0.0001).Table
40 
DAIC
FEBRUARY 3, 2025
This clearance comes in advance of disease-modifying therapies on the horizon expected to help clinicians use this biomarker to guide patients to improved cardiovascular health, saidBrad Moore, president and CEO at Roche Diagnostics North America. Circulation. The development of the Tina-quant Lipoprotein (a) Gen.2 Arnett DK et al.
Journal of the American Heart Association
JANUARY 16, 2025
BackgroundThe purpose of this study was to investigate whether circulating pyruvate kinase M2 (PKM2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in patients with heart failure (HF).Methods Journal of the American Heart Association, Ahead of Print. versus 7.82.3
Stroke Journal
JANUARY 30, 2025
Introduction:Peripheral blood-based biomarker development for neurological diseases such as ischemic stroke has traditionally focused on measuring alterations in leukocyte number and composition. Stroke, Volume 56, Issue Suppl_1 , Page ATP341-ATP341, February 1, 2025.
40 
Circulation: Heart Failure
JANUARY 16, 2025
Circulation: Heart Failure, Ahead of Print. Plasma levels of FMOD and FBLN5 were significantly associated with patient outcomes (P=0.005;P=0.004). BACKGROUND:Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis.
40 Circulation: Cardiovascular Quality & Outcomes
NOVEMBER 14, 2024
Circulation: Cardiovascular Quality and Outcomes, Volume 17, Issue 12 , Page e011483, December 1, 2024.
40 Frontiers in Cardiovascular Medicine
APRIL 5, 2024
Inhaled NO has the unique ability to exert its vasodilatory effects in the pulmonary vasculature without any hypotensive side-effects in the systemic circulation. Yet, various investigations failed to demonstrate significant differences in long-term clinical outcomes.
93 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4136687-A4136687, November 12, 2024. Patients' one-year clinical outcomes were evaluated.Results:The study found significant differences in VTRNA2-1 promoter methylation status between PAD patients and the control group (P < 0.001). 4.42, p=0.027).
Circulation: Heart Failure
MARCH 5, 2025
Circulation: Heart Failure, Ahead of Print. BACKGROUND:Exercise-induced hypertension (EIH) is common in adults with coarctation of the aorta (COA), but there are limited data about hemodynamics and outcomes in such patients.
40 
Journal of the American Heart Association
FEBRUARY 26, 2025
Implementation of fibrosis marker into TAVR risk stratification was tested by a machinelearning algorithm.ResultsAmong 20 circulating fibrosis markers involved in pathological extracellular matrix remodeling, high tissue inhibitor of metalloproteinase1 (TIMP1) levels independently predicted risk of death in univariable (hazard ratio, 5.0 [95%
45 
Stroke Journal
FEBRUARY 5, 2025
Growth Differentiation Factor 11 (GDF11), a member of the TGF- superfamily, is a circulating protein involved in cellular development and tissue repair. All six studies revealed consistent improvement of sensorimotor outcomes with rGDF11. Rats received single or multiple doses of rGDF11 (0.1-4
45 
DAIC
JANUARY 23, 2024
5 Over my career as a cardiovascular surgeon, as well as an immunologist, I have witnessed how current treatments for ASCVD have led to considerable improvements in outcomes, yet many patients remain vulnerable to life-threatening cardiac events.1,6 2019 Sep 10;140(11):e649-e650] [published correction appears in Circulation.
DAIC
MAY 8, 2024
The study was published today in Circulation Research , an American Heart Association journal, with Stefanos Zafeiropoulos, MD PhD , as the lead author and Stavros Zanos, MD PhD , as the senior author. The earlier and longer the treatment was delivered, the better the outcomes.
115 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4148010-A4148010, November 12, 2024. Further studies are required to determine if early initiation of therapies to improve RV systolic function in COVID-19 ECMO patients with ARDS improves outcomes.
40 
Heart BMJ
JANUARY 10, 2024
Objective Identification of patients at risk of adverse outcome from heart failure (HF) at an early stage is a priority. Growth differentiation factor (GDF)-15 has emerged as a potentially useful biomarker. Primary outcome was a composite of first hospitalisation for HF or all-cause mortality.
DAIC
MAY 6, 2024
The primary outcome measure for the study is change in six-minute walk distance from Baseline to Week 12. Approximately 152 subjects will be randomized in a 1:1 ratio to receive an oral dose of levosimendan (2 mg/day) or placebo for Weeks 1 to 4 and 3 mg/day or placebo for Weeks 5 to 12.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4113494-A4113494, November 12, 2024. These observed microbiota changes and metabolic shifts could serve as biomarkers for monitoring cell therapy and immunosuppression outcomes, offering potential therapeutic targets to enhance efficacy.
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4125093-A4125093, November 12, 2024. Inflammatory indicators such as neutrophil count and monocyte count potentially may predict patients’ outcomes and prognosis in ACS. Rate of MACE as composite outcome 30-days after PPCI as 24.7% (n=37).
40 
Circulation
OCTOBER 22, 2023
Circulation, Ahead of Print. The primary outcome was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding occurring between 3 and 12 months after index PCI. of patients were female and 55% presented with biomarker positive ACS. years, 23.2% vs. 2.1%; HR 0.37, 95% CI 0.24-0.56; 0.56; p < 0.001).
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141864-A4141864, November 12, 2024. Forin vitrostudies, we used bone marrow derived eosinophils and cell death assessed by biochemical and morphologic outcomes (annexin V binding, membrane permeabilization, citrullinated histone 3 (citH3), extracellular DNA and granule protein).Results:EHD
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4148181-A4148181, November 12, 2024. Background:Following an ischemic stroke, a serious complication known as hemorrhagic transformation (HT) might jeopardize patient outcomes.
40 
Circulation: Cardiovascular Quality & Outcomes
OCTOBER 20, 2023
Circulation: Cardiovascular Quality and Outcomes, Volume 16, Issue 11 , Page e009609, November 1, 2023. Further studies are needed to explore potential pathways between adverse cardiovascular disease outcomes and marijuana use. female; 13% non-Hispanic Black), 26.6% were current users. versus 3.0%,P=0.49), versus 24.2%,P=0.25),
40 
Circulation: Cardiovascular Quality & Outcomes
SEPTEMBER 2, 2024
Circulation: Cardiovascular Quality and Outcomes, Volume 18, Issue 1 , Page e011504, January 1, 2025. BACKGROUND:Risk stratification strategies for cancer therapeuticsrelated cardiac dysfunction (CTRCD) rely on serial monitoring by specialized imaging, limiting their scalability.
40 
DAIC
OCTOBER 2, 2024
vs 24% showed enhanced exercise capacity and 84% vs 8% demonstrated a substantial response in cardiac biomarkers (for all p aficamten achieved one or more clinically relevant outcomes, 62% achieved at least three outcomes and 23% achieved all four outcomes. mL/kg/min and ≥1 improvement in NYHA class, or pVO 2 ≥3.0
Stroke: Vascular and Interventional Neurology
JUNE 20, 2024
Moreover, the metabolism of certain substrates found in animal products (notablylcarnitine and choline) and of refined sugars by these microorganisms leads to buildup of circulating metabolites with known links to atherogenesis, platelet activation, atrial fibrillation, and other adverse vascular outcomes.
Circulation
NOVEMBER 12, 2023
Circulation, Ahead of Print. The primary outcome was the difference between groups in the distance (in meters) walked during the 6MWT at 6 months. Further research is needed to understand the disconnect between increased physical activity and functional outcomes. The control group patients continued usual care.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141170-A4141170, November 12, 2024. These findings suggest that 5-HTP could potentially be used as a biomarker for cardiovascular risk stratification. In cardiovascular research, serotonin has been implicated in modulating vascular tone, platelet aggregation, and myocardial function.
Dr. Smith's ECG Blog
AUGUST 9, 2024
Frick -- one wonders about the diagnosis of unstable angina in a patient with significantly elevated biomarkers which would certainly have been rising on repeat measurement.) Circulation Research , 56 (2), 184–194. Circulation , 63 (2), 333–340. Do not treat AIVR. In fact, use of antidyrhythimcs (e.g., Moffat, M. & Lukas, A.
107 
Stroke Journal
FEBRUARY 1, 2024
The primary outcome, presence of occult atrial fibrillation, was detected by ICM placement within 90 days and follow-up within 180 days from stroke. The adjusted OR (age ≥ 55, history of stroke, and history of TIA,) was 3.26, 95% CI: 1.0358-11.1860,P=.0480.Conclusion:The
Dr. Smith's ECG Blog
DECEMBER 11, 2023
The ESC states that patients with suspected ACS should go to the cath lab in ＜2 hours "regardless of ECG or biomarker evidence of MI!!" Circulation , 130 (25). link] Opiates are associated with worse outcomes in Myocardial Infarction. Mukherjee, D., Peterson, E. Sabatine, M. Smalling, R. & Zieman, S. link] Bischof, J.
Dr. Smith's ECG Blog
JANUARY 3, 2022
So even without the diagnostic ECGs, they had clinical evidence of refractory ischemia with biomarker (troponin) confirmation. Circulation 2014 7. -- McLaren JTT, Meyers HP, Smith SW, Chartier LB. Some have suggested that ECGs labeled “normal” are unlikely to have clinical significance, but this has been disputed.[5]
52 
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
IntroductionEndovascular thrombectomy (EVT) dramatically improves clinical outcomes, but the reduction in final infarct volume only accounts for 10‐15% of the treatment benefit. Univariate and multivariate logistic regression quantified the association between clinical/imaging variables and functional outcome. per 10mL; 95% CI: 0.66–0.99).
40 
DAIC
JANUARY 22, 2024
Kown, Asan Medical Center, Seoul, Korea Golden Bridge II Effect of an Artificial Intelligence-Based Clinical Decision Support System on Stroke Care Quality and Outcomes in Patients With Acute Ischemic Stroke : A Cluster-Randomized Clinical Trial: Zixiao Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, China Friday, Feb.
100 
Society of Thoracic Surgeons - Research
APRIL 20, 2023
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content